Skip to content
DraconiticResearch
Search Sources API
188,932 studies31 sourcesUpdated 55 min ago
PreprintCC BY-NCbioRxiv

Empirical Bayes Estimation of Sample-Specific Correlation Networks for Cross-Sectional and Longitudinal Omics Data

  1. 1University of South Carolina

Abstract

Sample-specific molecular networks, which capture how an individual's gene regulatory structure may deviate from the population as a whole, are important tools for understanding heterogeneity in health and disease. However, most existing methods either do not accommodate uncertainty quantification or cannot handle missing data, non-Gaussian modalities, and longitudinal structure common in modern multi-omic studies. For example, copy number alterations in cancer genomic studies are non-Gaussian and often only partially observed, and their regulatory effects on gene expression may vary substantially across patients, variation that a single, population-averaged network cannot capture. To address these challenges, we propose PRISM (Personalized Relational Inference via Sample-specific Modeling), an empirical Bayes framework for estimating sample-specific covariance matrices from cross-sectional and longitudinal multi-omic data. PRISM models each individual sample's covariance matrix as drawn from an inverse-Wishart prior whose parameters are estimated from the data and allowed to vary across subpopulations or evolve over time, yielding a closed-form posterior and edge-level uncertainty quantification, ensuring scalability to high-dimensional omics data. In simulation experiments, PRISM achieves point-estimate accuracy comparable to or better than existing methods, substantially improved uncertainty calibration under non-Gaussian marginals, and lower computational cost, while maintaining robust coverage under moderate missingness. We apply PRISM to a yeast cell-cycle time course dataset, recovering time-varying biologically meaningful regulatory relationships independently documented in literature, and to paired copy number and gene expression data from ovarian cancer patients, identifying copy-number-expression interactions associated with survival, including TFs HNF4G and PAX8 which have independent evidence of clinical relevance in this cancer.

Related

  1. Empirical Estimation of Ambient Contamination in Combinatorial Single-Cell Methods Using Multi-Reference Mapping
    F. Gomez-Cano, L. Jiang, J. D. Welch +1
    bioRxivPreprintCC BY-NC-NDFull textBioinformatics & computational biologybioRxiv
  2. Genome-wide LD scores enable robust heritability and genetic correlation estimation from summary statistics across genetic ancestries
    M. Jeong, Z. Liu, J. Ni +6
    bioRxivPreprintCC BY-NC-NDFull textGenetics & genomicsbioRxiv
  3. Longitudinal Subject Pairing in Cross-Sectional Neonatal Data Reveals Asynchronous Structural and Functional Brain Maturation
    R. Namiranian, M. Sadeghi, H. Abrishami Moghaddam
    bioRxivPreprintAll rights reservedFull textNeurosciencebioRxiv
  4. LoGicAl: local ancestry and genotype calling uncertainty-aware ancestry-specific allele frequency estimation from admixed samples
    Jiongming Wang, Sebastian Zöllner
    BioinformaticsPeer-reviewedCC BY 4.0Full textGenetics & genomicsPMC
  5. multiTEMPTED: Joint Dimensionality Reduction of Longitudinal Multi-omic Data with Modality-Specific Temporal Dynamics
    L. Lindsley, A. Settle, P. Shi
    bioRxivPreprintCC BY-NC-NDFull textBioinformatics & computational biologybioRxiv
BibTeX
@misc{saha2026empirical,
  title = {{Empirical Bayes Estimation of Sample-Specific Correlation Networks for Cross-Sectional and Longitudinal Omics Data}},
  author = {E. Saha and H. Chen and R. Ghosal},
  howpublished = {bioRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.08.757613},
  url = {https://www.biorxiv.org/content/10.64898/2026.10.08.757613v1},
  note = {CC BY-NC},
}
RIS
TY  - UNPB
TI  - Empirical Bayes Estimation of Sample-Specific Correlation Networks for Cross-Sectional and Longitudinal Omics Data
AU  - E. Saha
AU  - H. Chen
AU  - R. Ghosal
PY  - 2026
DA  - 2026/10/08
PB  - bioRxiv
DO  - 10.64898/2026.10.08.757613
UR  - https://www.biorxiv.org/content/10.64898/2026.10.08.757613v1
AB  - Sample-specific molecular networks, which capture how an individual's gene regulatory structure may deviate from the population as a whole, are important tools for understanding heterogeneity in health and disease. However, most existing methods either do not accommodate uncertainty quantification or cannot handle missing data, non-Gaussian modalities, and longitudinal structure common in modern multi-omic studies. For example, copy number alterations in cancer genomic studies are non-Gaussian and often only partially observed, and their regulatory effects on gene expression may vary substantially across patients, variation that a single, population-averaged network cannot capture. To address these challenges, we propose PRISM (Personalized Relational Inference via Sample-specific Modeling), an empirical Bayes framework for estimating sample-specific covariance matrices from cross-sectional and longitudinal multi-omic data. PRISM models each individual sample's covariance matrix as drawn from an inverse-Wishart prior whose parameters are estimated from the data and allowed to vary across subpopulations or evolve over time, yielding a closed-form posterior and edge-level uncertainty quantification, ensuring scalability to high-dimensional omics data. In simulation experiments, PRISM achieves point-estimate accuracy comparable to or better than existing methods, substantially improved uncertainty calibration under non-Gaussian marginals, and lower computational cost, while maintaining robust coverage under moderate missingness. We apply PRISM to a yeast cell-cycle time course dataset, recovering time-varying biologically meaningful regulatory relationships independently documented in literature, and to paired copy number and gene expression data from ovarian cancer patients, identifying copy-number-expression interactions associated with survival, including TFs HNF4G and PAX8 which have independent evidence of clinical relevance in this cancer.
ER  -